From Cord to Cure: CARTISTEM’s Stem Cell Revolution Targets Knee Woes

Writer: Sathirtha Mondal

Editor: Shane McGlone

Imagine your knees are the well-oiled hinges of a door that has been swinging non-stop for decades. Over time, with more wear and tear, the protective padding wears thin, and each creak instead becomes a grinding protest with a lot of pain. That’s the essence of osteoarthritis (OA), which targets weight-bearing spots like the knees where cartilage degeneration creates numerous complications for mobility and quality of life. With over 500 million people worldwide [1] battling this condition, understanding its roots and remedies is essential.

OA is a degenerative joint disease where the cartilage, a shock-absorbing tissue cushioning the ends of bones, breaks down over time. While age is a prime culprit with symptoms often kicking in after 50, this isn’t about just “getting old.” The entire joint gets involved: bones remodel, ligaments loosen, and the synovium, or the joint lining, inflames. This culminates in a vicious cycle of pain and stiffness. [2] Without their natural buffer, the bones in the knee rub together.

Early on, this presents as knee pain during activity, such as walking and climbing stairs. The pain and stiffness may be especially pronounced in the morning or after sitting. As it progresses, swelling, crepitus, or a crunchy sensation, and reduced range of motion become common, leading to instability. As it worsens, the pain may persist even during rest, disrupting sleep and daily life. [3]

What sparks OA?

Experts point to a mix of factors beyond inevitable aging. Primary OA stems from genetics and the natural thinning of cartilage with time. Secondary forms arise from clear triggers: previous injuries like ligament tears or fractures, obesity, repetitive high-impact activities, or underlying conditions that accelerate damage. [4] Women often face higher risks after menopause due to hormonal changes, while joint misalignment can lead to uneven wear. Inflammation and metabolic issues fan the flames, turning OA into a more multifaceted disease.

Sadly, there’s no outright cure, as mature cartilage has limited ability to regenerate on its own. Current treatments merely aim to manage symptoms, improve function, and slow progression. Among the least invasive options lie lifestyle changes, like weight loss, low-impact exercises like swimming and cycling, and physical therapy. Over-the-counter pain relievers such as acetaminophen handle basic discomfort, like NSAIDs like ibuprofen tackles pain and inflammation.

Should these options fall short, injections offer targeted relief: corticosteroids provide quick anti-inflammatory bursts, hyaluronic acid injections provide lubrication by mimicking the natural joint fluid, and emerging options like platelet-rich plasma or bone marrow aspirate try to utilize the body’s healing signals. For advanced cases, surgery is advised with procedures like arthroscopic debridement clearing loose debris, osteotomy realigning the bones to redistribute weight, and partial or total knee replacements swapping out damaged joints for a prosthetic. [5]

While these approaches provide meaningful relief and can significantly improve daily function, they largely manage symptoms rather than reverse the underlying cartilage loss.

In terms of rebuilding cartilage worn away by OA, CARTISTEM, an allogeneic stem cell therapy developed by South Korean biotech company MEDIPOST, has risen as a promising contender. CARTISTEM uses mesenchymal stem cells (MSCs) derived from donated umbilical cord blood, combined with a lyaluronate hydrogel scaffold that helps the cell integrate into the joint. [6] Delivered in a single-dose procedure, typically through arthroscopic injection, the cells work by modulating inflammation, secreting growth factors, and stimulating the regeneration of hyaline-like cartilage, the smooth tissue that cushions the joint. [6]

Since gaining approval from South Korea’s Ministry of Food and Drug Safety in 2012, CARTISTEM has treated over 30,000 patients with knee cartilage defects due to degenerative OA or repetitive trauma [7]. Clinical data from Korean studies, including a phase 3 comparison to microfracture (a common bone-marrow stimulation technique), have shown superior outcomes: better pain relief, improved joint function, and durable cartilage regeneration detected on MRI, with benefits lasting for years in most cases [8]

In early 2026, the U.S. Food and Drug Administration greenlighted a pivotal phase 3 trial for CARTISTEM. [9] This randomized, double-blind, multi-center study encompassing hundreds of patients across the U.S. and Canada will compare CARTISTEM to surgical debridement in people with moderate to severe knee OA. The first doses are expected in the first quarter of 2026 and a two-year follow-up is planned to assess efficacy, safety, and structural improvements. [10] If successful, the trial could position CARTISTEM as a disease-modifying osteoarthritis drug, a rare label that recognizes its ability to alter the disease course by regenerating cartilage.

While challenges like demonstrating long-term durability and navigating pricing and access in new markets lie ahead, treatments like CARTISTEM represent a shift from patching over the damage to actually repairing it, with several implications about the future of knee OA care.

References

1. World Health Organization. (2023, July 14). *Osteoarthritis*. https://www.who.int/news-room/fact-sheets/detail/osteoarthritis

2. Mayo Clinic. (2025, April 8). *Osteoarthritis - Symptoms & causes*. https://www.mayoclinic.org/diseases-conditions/osteoarthritis/symptoms-causes/syc-20351925

3. Cleveland Clinic. (2025, January 30). *Knee Osteoarthritis*. https://my.clevelandclinic.org/health/diseases/21750-osteoarthritis-knee

4. National Center for Biotechnology Information. (2023, June 26). *Knee Osteoarthritis*. In StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK507884/

5. Mayo Clinic. (2025, April 8). *Osteoarthritis - Diagnosis & treatment*. https://www.mayoclinic.org/diseases-conditions/osteoarthritis/diagnosis-treatment/drc-20351930

6. MEDIPOST Co., Ltd. (n.d.). *CARTISTEM®*. https://en.medi-post.co.kr/cartistem/

7. MEDIPOST Co., Ltd. (2024, June). *MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 Patients*. https://en.medi-post.co.kr/stem-cell-therapeutic/2024/06/37915/

8. Medipost Co Ltd. (n.d.). *Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury or Defect* (NCT01041001). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT01041001

9. Medipost, Inc. (n.d.). *Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis* (NCT07339111). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07339111

10. Korea Biomedical Review. (2026, February 4). *MEDIPOST scores FDA phase 3 green light for Cartistem in knee osteoarthritis*. https://www.koreabiomed.com/news/articleView.html?idxno=30536